Journal article

Low-dose IL-2 therapy invigorates CD8 T cells for viral control in systemic lupus erythematosus with a potential risk of deteriorating immunopathology.

Pengcheng Zhou, Jiali Chen, Jing He, Ting Zheng, Joseph Yunis, Victor Makota, Yannick O Alexandre, Fang Gong, Xia Zhang, Wuxiang Xie, Yuhui Li, Miao Shao, Yanshan Zhu, Jane E Sinclair, Miao Miao, Yaping Chen, Kirsty R Short, Scott N Mueller, Xiaolin Sun, Di Yu Show all

PLoS Pathog | Published : 2021

Abstract

Autoimmune diseases are often treated by glucocorticoids and immunosuppressive drugs that could increase the risk for infection, which in turn deteriorate disease and cause mortality. Low-dose IL-2 (Ld-IL2) therapy emerges as a new treatment for a wide range of autoimmune diseases. To examine its influence on infection, we retrospectively studied 665 patients with systemic lupus erythematosus (SLE) including about one third receiving Ld-IL2 therapy, where Ld-IL2 therapy was found beneficial in reducing the incidence of infections. In line with this clinical observation, Ld-IL2 treatment accelerated viral clearance in mice infected with influenza A virus or lymphocytic choriomeningitis virus ..

View full abstract

University of Melbourne Researchers

Grants